<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Perm Medical Journal</journal-id><journal-title-group><journal-title xml:lang="en">Perm Medical Journal</journal-title><trans-title-group xml:lang="ru"><trans-title>Пермский медицинский журнал (сетевое издание "Perm medical journal")</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0136-1449</issn><issn publication-format="electronic">2687-1408</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">112535</article-id><article-id pub-id-type="doi">10.17816/pmj401151-163</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Biology and experimental medicine</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Биология и экспериментальная медицина</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Morphological assessment of changes in internal organs of rats with introduction of targeted drug “Sutent” in experiment</article-title><trans-title-group xml:lang="ru"><trans-title>Морфологическая оценка изменений внутренних органов крыс при введении таргетного препарата «Сутент» в эксперименте</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0572-7594</contrib-id><contrib-id contrib-id-type="scopus">598754</contrib-id><name-alternatives><name xml:lang="en"><surname>Gulyaeva</surname><given-names>Natalya I.</given-names></name><name xml:lang="ru"><surname>Гуляева</surname><given-names>Наталия Ивановна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Candidate of Medical Sciences, leading researcher of the Central Scientific Research Laboratory</p></bio><bio xml:lang="ru"><p>кандидат медицинских наук, ведущий научный сотрудник ЦНИЛ</p></bio><email>bizon55@mail.ru</email><uri>https://e.mail.ru/inbox/</uri><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Vdovina</surname><given-names>G. P.</given-names></name><name xml:lang="ru"><surname>Вдовина</surname><given-names>Г. П.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Doctor of Pharmaceutical Sciences, Professor, Head of the Department of Pharmacology</p></bio><bio xml:lang="ru"><p>доктор фармакологических наук, профессор, заведующая кафедрой фармакологии</p></bio><email>bizon55@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Freind</surname><given-names>G. G.</given-names></name><name xml:lang="ru"><surname>Фрейнд</surname><given-names>Г. Г.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Professor, Head of the Department of Pathological Anatomy with Sectional Course</p></bio><bio xml:lang="ru"><p>доктор медицинских наук, профессор, заведующая кафедрой патологической анатомии с секционным курсом</p></bio><email>bizon55@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Burlutskaya</surname><given-names>A. A.</given-names></name><name xml:lang="ru"><surname>Бурлуцкая</surname><given-names>А. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Lecturer of the Department of Pharmacology</p></bio><bio xml:lang="ru"><p>преподаватель кафедры фармакологии</p></bio><email>bizon55@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Chugunova</surname><given-names>M. P.</given-names></name><name xml:lang="ru"><surname>Чугунова</surname><given-names>М. П.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Candidate of Pharmaceutical Sciences, leading researcher of the Central Scientific Research Laboratory</p></bio><bio xml:lang="ru"><p>кандидат фармакологических наук, ведущий научный сотрудник ЦНИЛ</p></bio><email>bizon55@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Karipova</surname><given-names>M. O.</given-names></name><name xml:lang="ru"><surname>Карипова</surname><given-names>М. О.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Assistant of the Department of Microbiology and Virology</p></bio><bio xml:lang="ru"><p>ассистент кафедры микробиологии и вирусологии</p></bio><email>bizon55@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">E.A. Vagner Perm State Medical University</institution></aff><aff><institution xml:lang="ru">Пермский государственный медицинский университет имени академика Е.А. Вагнера</institution></aff><aff><institution xml:lang="zh"></institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">E.A. Vagner Perm State Medical University</institution></aff><aff><institution xml:lang="ru">Пермский государственный медицинский университет имени академика Е.А. Вагнера</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2023-03-16" publication-format="electronic"><day>16</day><month>03</month><year>2023</year></pub-date><volume>40</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>151</fpage><lpage>163</lpage><history><date date-type="received" iso-8601-date="2022-11-13"><day>13</day><month>11</month><year>2022</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, Эко-Вектор</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://permmedjournal.ru/PMJ/article/view/112535">https://permmedjournal.ru/PMJ/article/view/112535</self-uri><abstract xml:lang="en"><p><bold>Objective.</bold> To establish in the experiment the changes in histological structure of the internal organs and blood indices in laboratory rats with intragastric introduction of the drug Sutent® in the doses of 7 mg/kg and 35 mg/kg of the weight.</p> <p><bold>Materials and methods.</bold> The study was conducted on 48 breedless white rats divided into the following groups: groups 1 and 4 – received cytotoxic drug Sutent® in the dose of 7 mg/kg (therapeutic dose), groups 2 and 5 – Sutent® in the dose of 35 mg/kg (fivefold exceeding the therapeutic dose), groups 3 and 6 – the control groups. In groups 1, 2, 3 animal were killed 30 days after the onset of the experiment, in groups 4, 5, 6 – two weeks after the drug withdrawal. Every day during 30 days, the experimental groups were introduced the intragastric drug Sutent® in the form of aqueous suspension in the purified water; in the control group the rats received the purified water in the equivalent volume. The histological preparations of organs stained with hematoxylin and eosin as well as the hematological indices of blood were investigated.</p> <p><bold>Results.</bold> The development of hypochromic anemia, thrombocytopenia and granulocytopenia in the was identified. While studying the histological structure of organs, in all experimental groups there was detected a disturbed circulation in the form of venous hyperemia and blood stasis in the capillaries, the development hemorrhages in the lung, liver, kidneys, adrenal glands, pancreas, gastric and esophageal mucosa. In the liver, pancreas and adrenal glands, dystrophic changes in the cells and necrosis foci were observed. In group 2, affection of the cerebral cortex nerve cells, heart cardiomyocytes, thyroid cells, acute duodenitis with formation of microabscesses was established.</p> <p><bold>Conclusions.</bold> Introduction of Sutent® in the dose of 35 mg/kg, compared with the dose of 7 mg/kg, caused a more expressed hematological, hepatological, cardiological and neurological toxicity, more obvious lesion of endocrine organs; it also contributed to the development of associated secondary infection and acute duodenitis.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Цель. </bold>Установить изменения гистологического строения внутренних органов и показателей крови у лабораторных крыс в эксперименте при внутрижелудочном введении препарата «Сутент®» в дозах 7 и 35 мг/кг веса.</p> <p><bold>Материалы и методы.</bold> Исследование проведено на 48 беспородных белых крысах, разделенных на группы: № 1 и 4 – получали цитотоксический препарат «Сутент®» в дозе 7 мг/кг (терапевтическая доза); № 2 и 5 – получали препарат в дозе 35 мг/кг (доза превышает терапевтическую в 5 раз); № 3 и 6 – контрольные группы. В группах № 1–3 забой животных производился через 30 дней после начала эксперимента, в группах № 4–6 – через две недели после отмены препарата. Ежедневно в течение 30 дней опытным группам вводили внутрижелудочно препарат «Сутент®» в виде водной суспензии в воде очищенной, в контрольной группе крысы получали воду очищенную в эквивалентном объеме. Изучались гистологические препараты органов, окрашенные гематоксилином и эозином, гематологические показатели крови.</p> <p><bold>Результаты.</bold> В крови установлено развитие гипохромной анемии, тромбоцитопении и гранулоцитопении. При изучении гистологического строения органов во всех экспериментальных группах выявлено нарушение кровообращения в виде венозного полнокровия и стаза крови в капиллярах, развитие кровоизлияний в легком, печени, почках, надпочечниках, поджелудочной железе, оболочках желудка и пищевода. В печени, поджелудочной железе и надпочечниках наблюдались дистрофические изменения клеток и фокусы некрозов. В группе № 2 было определено поражение нервных клеток коры головного мозга, кардиомиоцитов сердца, клеток щитовидной железы, развитие острого дуоденита с формированием микроабсцессов.</p> <p><bold>Выводы. </bold>Введение «Сутента» в дозе 35 мг/кг вызвало более выраженную по сравнению с дозой 7 мг/кг гематологическую, гепатологическую, кардиологическую и нейрологическую токсичность, более значительное поражение эндокринных органов, а также способствовало присоединению вторичной инфекции и развитию острого дуоденита.</p></trans-abstract><kwd-group xml:lang="en"><kwd>Sutent</kwd><kwd>experiment</kwd><kwd>histological structure of organs</kwd><kwd>blood</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>Сутент</kwd><kwd>эксперимент</kwd><kwd>гистологическое строение органов</kwd><kwd>кровь</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Blinov V.S., Blinova A.S., Petkau V.V., Demidov S.M. Criteria for responses of kidney cancer metastases to targeted and immunotherapy. J. Radiol. Nuclear Med. 2020; 101 (4): 206–213 (in Russian).</mixed-citation><mixed-citation xml:lang="ru">Блинов В.С., Блинова А.С., Петкау В.В., Демидов С.М. Критерии ответов метастазов рака почки на таргетную и иммунотерапию. Вестник рентгенологии и радиологии 2020; 101 (4): 206–213.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><mixed-citation>Yolla Haibe, Malek Kreidieh, Hiba El Hajj, Ibrahim Khalifeh, Deborah Mukherji, Sally Temraz, Ali Shamseddine. Resistance Mechanisms to Anti-angiogenic Therapies in Cancer. Front Oncol. 2020; 27 (10): 221.</mixed-citation></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Alekseev B.YA., Kalpinskij A.S., Muhomed'yarova A.A., Nyushko K.M., Kaprin A.D. Targeted therapy of patients with metastatic kidney cancer with an unfavorable prognosis. Oncourology 2017; 13 (2): 49–55 (in Russian).</mixed-citation><mixed-citation xml:lang="ru">Алексеев Б.Я., Калпинский А.С., Мухомедьярова А.А., Нюшко К.М., Каприн А.Д. Таргетная терапия больных метастатическим раком почки неблагоприятного прогноза. Онкоурология 2017; 13 (2): 49–55.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><mixed-citation>La Vine, D.B. T., Coleman T.A., Davis C.H., Carbonell C.E., Davis W.B. Frequent Dose Interruptions are Required for Patients Receiving Oral Kinase Inhibitor Therapy for Advanced Renal Cell Carcinoma. Am. J. Clinic. Oncology 2010; 33 (3): 217–220.</mixed-citation></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Alekseev B.YA., Kaprin A.D., Kolesnikov G.P., Muhomed'yarova A.A., Konopleva E.I., Kalpinskij A.S. Modern possibilities of treatment of metastatic renal cell carcinoma. Oncourology 2018; 14 (3): 25–35 (in Russian).</mixed-citation><mixed-citation xml:lang="ru">Алексеев Б.Я., Каприн А.Д., Колесников Г.П., Мухомедьярова А.А., Коноплева Е.И., Калпинский А.С. Современные возможности лечения метастатического почечноклеточного рака. Онкоурология 2018; 14 (3): 25–35.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Mashchelueva A.YU., Abramov M.E. Modern aspects of the use of Sutent in oncological practice. Effective pharmacotherapy 201; 3: 52–54 (in Russian).</mixed-citation><mixed-citation xml:lang="ru">Мащелуева А.Ю., Абрамов М.Е. Современные аспекты применения «Сутента» в онкологической практике. Эффективная фармакотерапия 2011; 3: 52–54.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Alekseev B.YA. Metastatic kidney cancer: the choice of first-line therapy. Oncourology 2014; 3: 43–48 (in Russian).</mixed-citation><mixed-citation xml:lang="ru">Алексеев Б.Я. Метастатический рак почки: выбор терапии первой линии. Онкоурология 2014; 3: 43–48.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Guidelines for the experimental (preclinical) study of new pharmacological substances. Edited by R.U. Khabrieva. Moscow: JSC "Publishing House "Medicine" 2005; 832 (in Russian).</mixed-citation><mixed-citation xml:lang="ru">Руководство по экспериментальному (доклиническому) изучению новых фармакологических веществ. Под ред. Р.У. Хабриева. М.: ОАО «Издательство «Медицина» 2005; 832.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Gutorov S.L., Borisova E.I. Practical recommendations for the prevention and correction of side effects of sunitinib. Oncourology 2010; 2: 8–13 (in Russian).</mixed-citation><mixed-citation xml:lang="ru">Гуторов С.Л., Борисова Е.И. Практические рекомендации по предотвращению и коррекции побочных эффектов сунитиниба. Онкоурология 2010; 2: 8–13.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Wenjing Luo, Chenggong Li, Yinqiang Zhang, Mengyi Du, Haiming Kou, Cong Lu, Heng Mei, Yu Hu. Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis.BMC. Cancer 2022; 22 (1): 98.</mixed-citation><mixed-citation xml:lang="ru">Wenjing Luo, Chenggong Li, Yinqiang Zhang,Mengyi Du, Haiming Kou, Cong Lu, Heng Mei, Yu Hu. Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis. BMC. Cancer 2022; 22 (1): 98.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Alekseev B.YA., Kalpinskij A.S. Targeted therapy of advanced kidney cancer with Sutent: side effects and their correction. Oncourology 2008; 3: 31–38 (in Russian).</mixed-citation><mixed-citation xml:lang="ru">Алексеев Б.Я., Калпинский А.С. Таргетная терапия распространенного рака почки Сутентом: побочные эффекты и их коррекция. Онкоурология 2008; 3: 31–38.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Hvastunov R.A., Skrypnikova G.V., Usachev A.A. Targeted therapy in oncology. Medicinal Bulletin 2014; 4 (56): 3–10 (in Russian).</mixed-citation><mixed-citation xml:lang="ru">Хвастунов Р.А., Скрыпникова Г.В., Усачев А.А. Таргетная терапия в онкологии. Лекарственный вестник 2014; 4 (56): 3–10.</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><mixed-citation>Fatema Tuz Zahra, Sanaullah Sajib, Constantinos M. Mikelis. Role of bFGF in Acquired Resistance upon Anti-VEGF Therapy in Cancer. Cancers (Basel) 2021; 13 (6): 1422.</mixed-citation></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Shaheen R.M., Tseng W.W., Davis D.W., Liu W., Reinmuth N., Vellagas R., Wieczorek A.A., Ogura Y., McConkey D.J., Drazan K.E., Bucana C.D., McMahon G., EllisL.M. Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms. Cancer Res. 2001; 61 (4): 1464–1468.</mixed-citation><mixed-citation xml:lang="ru">Shaheen R.M., Tseng W.W., Davis D.W., Liu W., Reinmuth N., Vellagas R., Wieczorek A.A., Ogura Y., McConkey D.J., Drazan K.E., Bucana C.D., McMahon G., Ellis L.M.. Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms. Cancer Res. 2001; 61 (4): 1464–1468.</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><mixed-citation>Terada T., Noda S., Inui K. Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors. Pharmacol Ther. 2015; 152: 125–134.</mixed-citation></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">Dorohina E.I. Long-term results and toxicity of high-dose chemotherapy in adult patients with diffuse B-large cell lymphoma according to the modified NHL-BFM-90 program: avtoref. dis. … kand. med. nauk. Moscow 2016; 26 (in Russian).</mixed-citation><mixed-citation xml:lang="ru">Дорохина Е.И. Отдаленные результаты и токсичность высокодозной химиотерапии взрослых больных диффузной В-крупноклеточной лимфомой по модифицированной программе NHL-BFM-90: автореф. дис. … канд. мед. наук. М. 2016; 26.</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">Du Souich P., Fradette C. The effect and clinical consequences of hepoxia on cytochrome P450, membrane carrier proteins activity and expression. Expert Opion Drug Metab. Toxicol. 2011; 7 (9): 1083–1100.</mixed-citation><mixed-citation xml:lang="ru">Du Souich P., Fradette C. The effect and clinical consequences of hepoxia on cytochrome P450, membrane carrier proteins activity and expression. Expert Opion. Drug Metab. Toxicol. 2011; 7 (9): 1083–1100.</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><mixed-citation>Chu T.F., Rupnick M.A., Kerkela R., Dallabrida S.M., Zurakowski D., Nguyen L., Woulfe K., Pravda E., Cassiola F., Desai J., George S., Morgan J.A., Harris D.M., Ismail N.S., Chen J.H., Schoen F.J., Van den Abbeele A.D., Demetri G.D., Force T., Chen M.H.Cl. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370: 2011–2019.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Wu M.D., Moslehi J.J., Lindner J.R. Arterial Thrombotic Complications of Tyrosine Kinase Inhibitors. Arterioscler. Thromb. Vasc. Biol. 2021; 41 (1): 3–10.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Duchnowska R., Loibl S., Jassem J. Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer. Cancer Treat. Rev. 2018; 67: 71–77.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>HutsonT.E., Figlin R.A., Kuhn J.G., Motzer R.J. Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing Strategies. Оncologist 2008; 13 (10): 1084–1096.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Rini B.I., Tamaskar I., Shaheen P., Salas R., Garcia J., Wood L., Reddy S., Dreicer R., Bukowski R.M. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J. Natl. Cancer. Inst. 2007; 99 (1): 81–83.</mixed-citation></ref><ref id="B23"><label>23.</label><citation-alternatives><mixed-citation xml:lang="en">Sikic D., Ludecke G., Lieb V., Keck B. Side effect management of tyrosine kinase inhibitors in urology: Fatigue and hypothyroidism. Urologe A. 2016; 55 (5): 648–652 (in German).</mixed-citation><mixed-citation xml:lang="ru">Sikic D., Lüdecke G., Lieb V., Keck B. Nebenwirkungsmanagement von Tyrosinkinaseinhibitoren in der Urologie: Fatigue und Hypothyreose. Urologe A. 2016; 55 (5): 648–652.</mixed-citation></citation-alternatives></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">Alekseev B.Ya., SHegaj P.V. Targeted therapy of advanced kidney cancer. Oncourology 2007; 4: 6–11 (in Russian).</mixed-citation><mixed-citation xml:lang="ru">Алексеев Б.Я., Шегай П.В. Таргетная терапия распространенного рака почки. Онкоурология 2007; 4: 6–11.</mixed-citation></citation-alternatives></ref><ref id="B25"><label>25.</label><citation-alternatives><mixed-citation xml:lang="en">Toropova I. Yu. Clinical monitoring of infectious complications in patients with hemoblastosis on the background of program chemotherapy: avtoref. dis. … kand. med. nauk. Moscow 2015; 24 (in Russian).</mixed-citation><mixed-citation xml:lang="ru">Торопова И.Ю. Клинический мониторинг инфекционных осложнений у больных гемобластозами на фоне программной химиотерапии: автореф. дис. … канд. мед. наук. М. 2015; 24.</mixed-citation></citation-alternatives></ref><ref id="B26"><label>26.</label><citation-alternatives><mixed-citation xml:lang="en">Sakaeva D.D., Orlova R.V., SHabaeva M.M. Practical recommendations for the treatment of infectious complications of febrile neutropenia and the appointment of colony-stimulating factors in cancer patients. Russian Society of Clinical Oncology 2019; 9 (3s2): 585–594 (in Russian).</mixed-citation><mixed-citation xml:lang="ru">Сакаева Д.Д., Орлова Р.В., Шабаева М.М. Практические рекомендации по лечению инфекционных осложнений фебрильной нейтропении и назначению колониестимулирующих факторов у онкологических больных. Russian Society of Clinical Oncology 2019; 9 (3s2): 585–594.</mixed-citation></citation-alternatives></ref><ref id="B27"><label>27.</label><mixed-citation>Gazzaniga G., Villa F., Tosi F., Pizzutilo E.G., Colla S., D’Onghia S, Di Sanza G., Fornasier G., Gringeri M., Lucatelli M.V., Mosini G., Pani A., Siena S., Scaglione F., Sartore-Bianchi A. Pneumatosis Intestinalis Induced by Anticancer Treatment: A Systematic Review. Cancers 2022; 14: 1666.</mixed-citation></ref></ref-list></back></article>
